X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PFIZER - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PFIZER IPCA LABS/
PFIZER
 
P/E (TTM) x 29.0 34.3 84.4% View Chart
P/BV x 3.7 4.8 76.0% View Chart
Dividend Yield % 0.1 0.7 18.1%  

Financials

 IPCA LABS   PFIZER
EQUITY SHARE DATA
    IPCA LABS
Mar-18
PFIZER
Mar-18
IPCA LABS/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6952,365 29.4%   
Low Rs4001,625 24.6%   
Sales per share (Unadj.) Rs260.2430.3 60.5%  
Earnings per share (Unadj.) Rs19.078.7 24.1%  
Cash flow per share (Unadj.) Rs33.193.2 35.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.21.0 18.2%  
Book value per share (Unadj.) Rs213.0586.5 36.3%  
Shares outstanding (eoy) m126.2045.75 275.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.6 45.4%   
Avg P/E ratio x28.925.3 113.9%  
P/CF ratio (eoy) x16.621.4 77.4%  
Price / Book Value ratio x2.63.4 75.6%  
Dividend payout %5.325.4 20.7%   
Avg Mkt Cap Rs m69,12091,271 75.7%   
No. of employees `00013.32.6 504.0%   
Total wages/salary Rs m7,3593,143 234.1%   
Avg. sales/employee Rs Th2,477.47,484.8 33.1%   
Avg. wages/employee Rs Th555.21,195.0 46.5%   
Avg. net profit/employee Rs Th180.61,369.1 13.2%   
INCOME DATA
Net Sales Rs m32,83619,685 166.8%  
Other income Rs m4181,143 36.6%   
Total revenues Rs m33,25420,828 159.7%   
Gross profit Rs m4,5055,003 90.0%  
Depreciation Rs m1,777663 268.3%   
Interest Rs m2404 5,719.0%   
Profit before tax Rs m2,9055,479 53.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,878 27.2%   
Profit after tax Rs m2,3943,601 66.5%  
Gross profit margin %13.725.4 54.0%  
Effective tax rate %17.634.3 51.3%   
Net profit margin %7.318.3 39.9%  
BALANCE SHEET DATA
Current assets Rs m19,45524,167 80.5%   
Current liabilities Rs m10,0769,544 105.6%   
Net working cap to sales %28.674.3 38.5%  
Current ratio x1.92.5 76.3%  
Inventory Days Days9855 177.7%  
Debtors Days Days6729 233.2%  
Net fixed assets Rs m20,2609,514 213.0%   
Share capital Rs m252458 55.2%   
"Free" reserves Rs m26,63326,375 101.0%   
Net worth Rs m26,88626,832 100.2%   
Long term debt Rs m2,34025 9,360.4%   
Total assets Rs m41,17336,900 111.6%  
Interest coverage x13.11,305.5 1.0%   
Debt to equity ratio x0.10 9,341.7%  
Sales to assets ratio x0.80.5 149.5%   
Return on assets %6.49.8 65.5%  
Return on equity %8.913.4 66.4%  
Return on capital %10.820.4 52.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64222 69,830.8%   
Fx outflow Rs m4,8841,489 328.0%   
Net fx Rs m10,759-1,466 -733.7%   
CASH FLOW
From Operations Rs m3,4113,318 102.8%  
From Investments Rs m-1,354-2,383 56.8%  
From Financial Activity Rs m-1,304-1,104 118.2%  
Net Cashflow Rs m753-169 -447.0%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.4 7.5 152.0%  
FIIs % 25.3 4.9 516.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.7 73.4%  
Shareholders   36,892 85,207 43.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Sensex Ends 77 Points Higher(Closing)

Indian share markets witnessed buying interest during closing hours and ended on a positive note. Gains were seen in the metal sector.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Dec 18, 2018 03:35 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS